DBV Technologies S.A. (DBVT)

Market Cap	119.97M
Revenue (ttm)	4.20M
Net Income (ttm)	-113.90M
Shares Out	96.50M
EPS (ttm)	-1.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,716,338
Open	6.05
Previous Close	3.91
Day's Range	5.30 - 6.78
52-Week Range	0.44 - 6.78
Beta	0.92
Analysts	Strong Buy
Price Target	22.50 (+262.9%)
Earnings Date	May 6, 2025

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respirato...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 105
• Stock Exchange: NASDAQ
• Ticker Symbol: DBVT
• Website: https://www.dbv-technologies.com

Financial Performance

In 2024, DBV Technologies's revenue was $4.20 million, a decrease of -73.30% compared to the previous year's $15.73 million. Losses were -$113.90 million, 56.6% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for DBVT stock is "Strong Buy." The 12-month stock price forecast is $22.5, which is an increase of 262.90% from the latest price.

Price Target

$22.5

(262.90% upside)

Analyst Consensus: Strong Buy